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Background: HIV-infected individuals have an increased risk of cardiovascular disease (CVD). T-allele carriers of the
CD14 C-260T single-nucleotide polymorphism (SNP) have reported increased expression of the LPS-binding receptor,
CD14 and inflammation in the general population. Our aim was to explore the relationship of this SNP with monocyte/
macrophage activation and inflammation and its association with sub-clinical atherosclerosis in HIV-infected individuals.
Methods: Patients with no pre-existing CVD risk factors on suppressive antiretroviral therapy were recruited from
University Malaya Medical Centre, Malaysia (n = 84). The CD14 C-260T and TLR4 SNPs, Asp299Gly and Thr399Ile
were genotyped and soluble(s) CD14 and sCD163 and high-sensitivity C-reactive protein, hsCRP were measured
in plasma. Subclinical atherosclerosis was assessed by measuring carotid intima media thickness (cIMT). The association
between CD14 C-260T SNP carriage and cIMT was assessed in a multivariable quantile regression model where a p-value
of <0.05 was considered significant.
Results: We found the CD14 C-260T T-allele in 56% of the cohort and evidence of subclinical atherosclerosis in 27%. TT
genotype was associated with higher sCD163 (p = 0.009) but only marginally higher sCD14 (p = 0.209) and no difference
in hsCRP (p = 0.296) compared to CC/CT. In multivariable analysis, only Framingham risk score was independently
associated with higher cIMT while lower sCD163 was trending towards significance. No association was found in
TT-genotype carriers and cIMT measurements.
Conclusion: The CD14 C-260T SNP was associated with increased monocyte activation but not systemic inflammation
or cIMT in this HIV-infected cohort with low CVD risk profile.
Keywords: HIV, Lipopolysaccharide, CD12 C-260T, Soluble CD14, Soluble CD163, Monocyte activation, C-reactive protein,
Atherosclerosis, Carotid intima media thicknessBackground
Persistent immune activation and inflammation have
been well described in chronic HIV disease (reviewed in
[1]) and have been associated with an increased risk of
atherosclerosis in this population [2-6]. Many factors
contribute to chronic immune activation including the
translocation of microbial products including lipopoly-
saccharide (LPS) from damaged gut-associated lymphoid* Correspondence: reena@um.edu.my
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unless otherwise stated.tissue sustained during early HIV disease [7,8]. Chronic
elevation of LPS persists despite suppressive combination
antiretroviral therapy (cART) [7,9] and may drive in-
creased cardiovascular disease (CVD) risk in HIV-infected
individuals [2,10] as has been found in HIV-negative pop-
ulations [11-13].
CD14 is a co-receptor for LPS, and together with MD-2
binds to toll-like receptor 4 (TLR4) on monocytes and
macrophages activating them (reviewed in [14]). There is
also a soluble form for CD14 (sCD14) which is secreted by
monocytes/macrophages following LPS stimulation and
by liver cells as an acute-phase protein following stimula-
tion by IL-6 [15]. Soluble CD14 plays an important role inral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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membrane-bound CD14 including endothelial and epithe-
lial cells [16].
A common polymorphism in the CD14 gene, C-260T
has been associated with differential expression levels
of CD14 on monocytes/macrophages [17-19]. The SNP
(C→ T) occurs in the promoter region of the CD14
gene and increases the binding affinity of specificity
protein (Sp) transcription factors [20], leading to subsequent
increases in CD14 production [20,21]. T vs C allele carriers
have been found to have higher density of membrane-
bound CD14 and circulating levels of sCD14 [18,19,22]
and subsequent increased production of pro-inflammatory
cytokines following LPS stimulation [19,21,23]. This in
turn may influence the development and progression of
atherosclerotic disease. Conversely, two non-synonymous
SNPs in the TLR4 gene, Asp299Gly and Thr399Ile, have
been associated with reduced cytokine responses following
LPS stimulation in some studies [24,25] and the carriage of
these SNPs may also modulate LPS-mediated responses.
In genotype-phenotype studies, the association between
the C-260T single nucleotide polymorphism (SNP) and
cardiovascular disease have been mixed with some studies
reporting a positive association while others have not
[18,22,26-31]. Two comprehensive meta-analyses have
however suggested that this association may be more
relevant in East Asians compared to Caucasians [32,33].
Given the association between LPS-mediated monocyte/
macrophage activation and CVD in HIV-infected individ-
uals [10,34,35], we hypothesised that the CD14 (C-260T)
SNP would be associated with increased risk of CVD in an
Asian cohort of HIV-infected individuals. To help better
delineate the potential influence of this SNP from other
metabolic processes known to increase CVD risk, the
study was conducted in patients who reported no clinical
history of CVD risk factors (IHD, diabetes, hypertension
or dyslipidemia) at recruitment. Our aims were 1) to ex-
plore the relationship between the CD14 C-260T SNP on
markers of monocyte/macrophage activation (including
soluble(s) CD14 and sCD163) and inflammation (as mea-
sured by highly sensitive C-reactive protein (hsCRP) and
2) to assess the association between the CD14 C-260T




This was a sub-study of a clinic-based cohort that was
established to study the prevalence of metabolic syndrome
and subclinical atherosclerosis among HIV-infected indi-
viduals attending the University Malaya Medical Centre
(UMMC), Malaysia. Participants in the sub-study were re-
consented for genetic testing. The inclusion criteria were;
receiving cART for a minimum duration of 6 months, noevidence of symptomatic AIDS in the last 6 months,
no pre-existing clinical history of CVD or other athero-
sclerotic disease including cerebrovascular or peripheral
vascular disease, pregnancy, hypertension, diabetes mel-
litus, dyslipidemia and malignancies.
Subclinical atherosclerosis was assessed by measurement
of cIMT with high-resolution ultrasonography (Philips
IU-22, USA) at 6 sites; right and left mid common ca-
rotid arteries, carotid bifurcation and the proximal site
of the internal carotid arteries. Measurements of cIMT
from left and right arteries were pooled and mean values
were used for each patient. Subclinical atherosclerosis was
defined as a mean cIMT > 0.7 mm as previously described
[36], the presence of plaque (focal echogenic structure
with cIMT > 1.2 mm) or both. Additionally, screening for
traditional cardiovascular risk factors including fasting
blood glucose, lipid profile, anthropometric measure-
ments, resting blood pressure and assessment of smoking
status and family history for premature cardiovascular
disease (CVD) were performed. Data on HIV-specific
characteristics including HIV RNA, CD4 T-cell counts,
antiretroviral drug history and history of co-infections
were obtained from patient medical records.
The study was approved by the hospitals institutional
review board (MEC 975.6).
Specimen collection, genotyping and measurement of
immune activation markers
Whole blood was collected in EDTA-vacutainers. Peripheral
blood mononuclear cells (PBMCs), plasma and neutrophils
were isolated as previously described [37]. DNA was ex-
tracted using the Qiagen Blood and Tissue kit (Qiagen,
Germany) from neutrophils and genotyped for the CD14
(rs2569190) and TLR4 (rs4986790 and rs2569190) SNPs
at the Australian Genome Research Facility (AGRF) using
the Sequenom MassArray platform. Markers of monocyte
activation including sCD14 (R&D Systems, McKinley
Place, MN) and sCD163 (Trilium Diagnostics, Bangor,
ME) were measured by ELISA in plasma according to
the manufacturer’s instructions. The systemic inflamma-
tion marker, hsCRP was determined by immunochem-
iluminometric assay by the hospitals clinical diagnostic
laboratory.
Statistical analysis
Categorical variables were summarized using frequency
and percentage. Continuous variables were tested for
skew using a Shapiro-Wilk test and summarized using
mean and standard deviation (SD) or median and inter-
quartile range (IQR) as appropriate. Chi-square analysis
was used to test Hardy-Weinberg equilibrium (HWE).
The influence of CD14 C-260T genotypes on markers of
immune activation, inflammation and cardiovascular
risk factors were compared using Mann Whitney U or
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was chosen as the primary model of analysis given prior
reports of a higher odds of SNP association when using
this model compared to a recessive model in cohorts of
East Asian ethnicity [33]. Median quantile regression ana-
lysis was then used to assess the independent influence of
the CD14 SNP on cIMT adjusting for traditional cardio-
vascular risk factors and HIV-related parameters. Using
quantile regression to model median cIMT was preferred
over simple regression of the mean secondary to signifi-
cant skew in cIMT which was not able to be corrected
using standard transformations (log-, square-root or in-
verse Gaussian transformations). As such the key under-
lying assumption for outcome variable normality required
by regression models of the mean was not able to be satis-
fied. A quantile regression by comparison does not assume
underlying normality and is thus far more robust to non-
normal errors and outliers. Parameters were log trans-
formed if they were significantly skewed or if their effect
sizes (coefficients) were too small or clinically meaning-
less if left untransformed. Co-variates for the multivari-
able model were selected based on a semi-backwards/
semi-frontwards/semi-a priori modelling approach where
the a priori assumption was that covariates significant at a
p < 0.20 level in the univariable model was considered a
candidate predictor to be included in the multivariable
analysis. All statistical analysis was performed using Stata
version 12 (StataCorp, College Station, Texas).
Results
Cohort characteristics and distribution of CD14 (C-260T) SNP
Patients were identified from a pre-existing study asses-
sing the prevalence of metabolic syndrome and subclin-
ical atherosclerosis among HIV-infected individuals on
cART. A total of 84 patients consented for genetic testing
from the initial cohort of 126. Most patients were male
with a median (IQR) age of 41 (36 -46) years (Table 1). All
patients had received cART for a median (IQR) duration
of 4 (1-8) years. The majority received non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based regimens
(88%) while 11% received a protease inhibitor (PI)-based
regimen. Only one patient had prior exposure to the nu-
cleoside reverse transcriptase inhibitor (NRTI), abacavir
(1.1%) and three with a PI-based regimen (4%). The cohort
in general had low CVD risk with the median (IQR)
10-year Framingham risk score of 5% (3–11). Twenty
seven percent of the cohort had evidence of subclinical
atherosclerosis defined by an increase in mean cIMT
of >0.7 mm or the presence of plaque.
T-allele carriage for the CD14 (C-260T) SNP was 56%
and the genotype distribution was in HWE (p = 0.718).
The genotype call rate was 95.2%. We additionally geno-
typed the TLR4 Asp299Gly and Thr399Ile SNPs to ad-
dress possible gene-gene interactions with the CD14(C-260T) SNP but found only one patient heterozygous
for the TLR4 SNPs while the remaining were wild type
carriers. The TLR4 SNPs were therefore not considered in
subsequent analysis.
Association between CD14 C-260T SNP and markers of
monocyte activation and systemic inflammation
We assessed the influence of CD14 C-260T SNP on
markers of monocyte activation and systemic inflamma-
tion. There was no significant difference in the concentra-
tion of sCD14 between CC/CT vs TT genotype carriers
(p = 0.266) but TT genotype carriers had significantly
higher sCD163 levels compared to CC/CT carriers (p =
0.008) (Table 2). The associations did not change when
controlling for the effects of smoking, current CD4 T-cell
counts, age and gender, factors previously shown to
strongly influence monocyte/macrophage activation levels
[38-40]. There was no significant difference in the median
concentration of hsCRP in the two groups, however
hsCRP was significantly correlated with levels of sCD14
(p = 0.030) and sCD163 (p = 0.022) (Figure 1). These as-
sociations remained unchanged when analysis was done
using a recessive model (CC vs CT/TT, data not shown).
Association between CD14 C-260T SNP and increased cIMT
We next assessed if the CD14 C-260T SNP was inde-
pendently associated with increased cIMT using a multi-
variate regression model adjusting for both HIV-specific
clinical parameters and traditional cardiovascular risk
factors. In univariable analysis, we found only increasing
age and Framingham score were significantly associated
with increased cIMT, while log current CD4 T-cell counts
and log sCD163 levels were candidate predictors based on
p-value thresholds set a priori, p < 0.20. In the multivari-
able model however, only higher Framingham risk score
was independently associated with higher cIMT while
there was a trend that lower log sCD163 levels was associ-
ated with increased cIMT (Table 3).
Discussion
This is the first study to assess the potential modifying
effect of the CD14 C-260T SNP on monocyte activation
and inflammation in HIV-infected individuals. In this
clinic-based cohort of HIV-infected patients on cART
who had a no clinical history of CVD, diabetes, hyper-
tension and dyslipidemia at recruitment, 27% had evidence
of sub-clinical atherosclerosis defined by increased
cIMT >0.7 mm. The CD14 C-260T T-allele was the
major allele carried in 56% of the cohort and consistent
with the reported distribution among Asians in Hapmap.
In a multivariable analysis, the CD14 C-260T SNP was
however not associated with sub-clinical atherosclerosis as
measured by cIMT in this treated HIV cohort.
Table 1 Cohort characteristics according to the CD14 C-260T SNP distribution
Patient characteristics CD14 C-260T genotype# Total cohort (N = 84)*
CC (n = 15)* CT (n = 41)* TT (n = 24)*
Age, years 38 (32–48) 41 (37–45) 41 (36–48) 41 (36–46)
Gender, n (%) male 13 (86.7%) 33 (80.5%) 17 (70.8%) 67 (79.8%)
Ethnicity, n (%)
- Malay 7 (46.7%) 7 (17.1%) 3 (12.5%) 19 (22.6%)
- Chinese 7 (46.7%) 28 (68.3%) 19 (79.2%) 56 (66.7%)
- Indian 1 (6.7%) 6 (14.6%) 2 (8.3%) 9 (10.7%)
Baseline CD4 T-cell count, cells/μl 30 (8–253) 106 (13–223) 60 (22–197) 63 (16–228)
Current CD4 T-cell count, cells/μl 300 (155–450) 386 (286–536) 468 (292–631) 387 (271–547)
Current CD4:CD8 ratio 0.36 (0.17–0.55) 0.54 (0.33–0.73) 0.59 (0.28–0.79) 0.51 (0.28–0.74)
Baseline HIV RNA, copies/ml 163693 (59611–559681) 137600 (50158–316679) 105659 (33069–404288) 136423 (52214–398660)
Duration on ARV, years 2 (1–6) 5 (3–10) 7 (2–10) 4 (1–8)
Current ARV regimen, n (%)
- NNRTI-based 13 (86.7%) 36 (87.8%) 21 (87.5%) 74 (88.1%)
- PI-based 2 (13.3%) 5 (12.2%) 3 (12.5%) 10 (11.9%)
Previous abacavir use, n (%) 1 (2.4%) 1 (1.1%)
Previous PI use, n (%) 3 (7.3%) 3 (3.6%)
Positive hepatitis C antibody, n (%) 0 (0.0%) 0 (0.0%) 1 (4.2%) 2 (2.4%)
Positive hepatitis B surface antigen, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Smoking, n (%)
- Never 9 (60.0%) 24 (58.5%) 12 (50.0%) 46 (54.8%)
- Former 2 (13.3%) 4 (9.8%) 4 (16.7%) 10 (11.9%)
- Current 4 (26.7%) 13 (31.7%) 8 (33.3%) 28 (33.3%)
Framingham risk score, % 5.85 (1.88–11.45) 5.05 (2.93–8.63) 4.75 (2.23–14.80) 5.00 (2.75–11.05)
Body mass index, kg/m2 22.3 (19.8–25.1) 22.6 (21.4–25.4) 24.1 (20.8–26.2) 23.0 (21.2–25.5)
Family history CVD, n (%) 1 (6.7%) 7 (17.1%) 0 (0.0%) 8 (9.5%)
Diabetes, n (%) 0 (0.0%) 1 (2.4%) 2 (8.3%) 4 (4.8%)
Hypertension, n (%) 9 (60.0%) 14 (34.1%) 8 (33.3%) 32 (38.1%)
Fasting glucose, mmol/L 4.8 (4.5–5.5) 5.2 (4.9–5.5) 5.3 (4.7–5.8) 5.1 (4.7–5.6)
Total cholesterol, mmol/L 5.4 (4.2–5.8) 5.2 (4.7–6.2) 5.2 (4.8–5.6) 5.2 (4.6–5.8)
LDL, mmol/L 2.8 (2.5–3.6) 3.1 (2.5–3.9) 3.1 (2.6–3.5) 3.0 (2.5–3.6)
HDL, mmol/L 1.2 (0.9–1.5) 1.2 (1.0–1.5) 1.1 (0.9–1.3) 1.2 (0.9–1.4)
Triglycerides, mmol/L 2.0 (1.4–2.8) 1.8 (1.5–2.3) 2.1 (1.5–3.3) 1.9 (1.4–2.5)
Increased cIMT, (>0.7 mm), n (%) 3 (20.0%) 13 (31.7%) 6 (25.0%) 23 (27.4%)
TLR4 frequency, n (%)
- TLR4 Asp299Gly (c.896A > G) (rs4986790) 1 (2.4%) 1 (1.1%)
- TLR4 Thr399Ile (c.1196C > T) (rs2569190) 1 (2.4%) 1 (1.1%)
*Data shown are median (IQR) unless otherwise stated; #4 patients did not have CD14 C-260T genotype data; ARV: antiretroviral therapy, NNRTI: non-nucleoside
reverse transcriptase inhibitors, PI: protease inhibitors; CVD: cardiovascular disease; LDL: low-density lipoprotein; HDL: high-density lipoprotein, cIMT: carotid intima
media thickness, TLR4: toll-like receptor 4.
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homozygous vs CC/CT carriers. Soluble CD163 is a
hemoglobin-heptoglobin scavenging receptor that is shed
from monocyte/macrophages following pro-inflammatory
stimulation including LPS [41,42] and therefore considereda marker of monocyte activation. Functionally however,
sCD163 has been described to have a role in attenuating
inflammatory processes (reviewed in [43]). In HIV-infected
individuals, sCD163 levels positively correlated with
monocyte and T-cell activation and inversely with CD163
Table 2 Comparison of markers of immune activation, inflammation and cardiovascular risk factors among the CD14
C-260T CC/CT vs TT carriers
CC/CT (n = 56)* TT (n = 24)* p pΔ
Immune activation and inflammatory markers
Log sCD14 6.20 (6.11–6.28) 6.24 (6.15–6.30) 0.266§ 0.188
Log sCD163 2.94 (2.84–3.07) 3.03 (2.97 3.20) 0.008§ 0.013
Log hsCRP -0.77 (-0.32 - -1.08) -0.53 (-0.26 - -0.95) 0.296§ 0.232
Cardiovascular risk factors
Body mass index, kg/m2 22.4 (20.9–25.2) 23.9 (20.6–26.0) 0.482§
Fasting sugar, mmol/L 5.0 (4.6–5.5) 5.1 (4.6–5.8) 0.298§
Total cholesterol, mmol/L 5.2 (4.6–6.0) 5.1 (4.8–5.6) 0.858§
Triglyceride, mmol/L 1.8 (1.4–2.3) 2.0 (1.5–2.8) 0.239§
HDL, mmol/L 1.24 (0.99–1.49) 1.12 (0.90–1.31) 0.087§
LDL, mmol/L 2.9 (2.5–3.8) 3.1 (2.6–3.5) 0.978§
Age, years 41 (36–46) 41 (36–48) 0.961§
Male gender, % 82.1% 70.8% 0.257#
Current smoker, % 30.4% 33.3% 0.792#
Framingham risk score 5.05 (2.80–9.08) 4.75 (2.23–14.80) 0.925§
*Data shown are median (IQR) unless otherwise stated; §p-value for Mann-Whitney U; #p-value for Chi-square test; Δp-value adjusted for smoking status, current
CD4 T-cell counts, age and gender.
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we have not found any prior studies that have assessed the
association between the CD14 C-260T SNP and sCD163
in the general population. Our findings that sCD163 are
increased with the CD14 C-260T TT genotype implies
that carriers of this genotype have increased monocyte
activation.
Prior studies in HIV-infected individuals on cART
found increased monocyte activation was an independent
predictor of CVD [10,34,35,45-48] and mortality [49]. A
recent study found that monocyte activation and not
T-cell activation was strongly associated with markers
of systemic inflammation and coagulation (IL-6, hsCRP
and D-dimers) which has been shown to predict many
serious non-AIDS events (SNAEs) and mortality in HIV-
infected individuals [50]. Therefore in HIV-infected indi-
viduals, TT genotype carriers may be at a higher risk
of SNAEs due to increased monocyte activation. LargerFigure 1 Correlation between systemic inflammation and monocyte a
markers of monocyte activation, (A) Log sCD14 (p = 0.030, Spearman correprospective studies assessing the association of this SNP
with more detailed characterisation of monocyte activa-
tion markers and clinical end-points will be needed to
confirm this.
In this study, we found no significant difference in
sCD14 levels in homozygous TT vs CC/CT carriers with
and without adjusting for current CD4 T-cell counts,
smoking status, age and gender. The lack of statistical
significance could potentially be due to the small sample
numbers in our study or due to the influence of other
SNPs not measured in this study that could have add-
itional modulating effects on sCD14 levels. A recent
genome wide association study (GWAS) in 5000 older
individuals (>65 years) identified 164 SNPs which were
associated with sCD14 levels and responsible for ap-
proximately 33% of the phenotypic variance [13]. Some
studies of the CD14 C-260T SNP in the general popula-
tion have found T vs C allele carriers had increasedctivation markers. Correlation between levels of Log hsCRP and
lation) and (B) Log sCD163 (p = 0.022) measured in the cohort (n = 84).
Table 3 Risk factors associated with carotid intima media






Age, years 0.007 (0.004, 0.011) <0.001*
Body mass index, kg/m2 0.006 (-0.005, 0.017) 0.273
Total cholesterol, mmol/L 0.015 (-0.021, 0.051) 0.415
Triglyceride, mmol/L 0.003 (-0.029, 0.029) 0.985
HDL, mmol/L -0.001 (-0.105, 0.103) 0.984
LDL, mmol/L 0.019 (-0.022, 0.060) 0.369
Fasting glucose, mmol/L -0.017 (-0.053, 0.020) 0.366
Framingham score, % 0.011 (0.006, 0.016) <0.001
Baseline CD4 T-cell counts, per
100 cells/μl
-0.011 (-0.044, 0.022) 0.527
Log baseline HIV RNA -0.006 (-0.028, 0.016) 0.585
Log current CD4 T-cell counts 0.043 (-0.016, 0.104) 0.151
Log sCD14 0.020 (-0.083, 0.123) 0.700
Log sCD163 -0.054 (-0.135, 0.027) 0.190
Log hsCRP 0.0005 (-0.025, 0.026) 0.970
CD14 C-260T genotype;
CC/CT vs TT
-0.013 (-0.099, 0.071) 0.758
Multivariable model
Framingham score, % 0.009 (0.004, 0.014) <0.001
Log current CD4 T-cell counts 0.038 (-0.033, 0.108) 0.289
Log sCD163 -0.084 (-0.182, 0.013) 0.087
*Age was omitted from the multivariable model given that it is one of the
components used to derive the Framingham risk score.
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not all studies have found this association [30,51]. In
vitro studies have also found the T vs C allele was asso-
ciated with increased inducible sCD14, TNFα and IL-6
production following LPS-stimulation of whole blood
[19,21,23] but we did not measure these parameters in
this study.
We did not find a significant difference in the median
levels of hsCRP in TT vs CC/CT carriers. Increases in
hs-CRP have been shown to correlate with the extent of
vascular disease measured by the presence of vascular
dysfunction in multiple vascular beds (carotid, coronary
and brachial artery) [34]. Indeed, most studies that
have found an association between hsCRP and the CD14
C-260T SNP [23,52,53] have so far been in populations
that have already developed cardiovascular disease and
unlike our study participants who had subclinical disease.
This difference in cohort characteristic may have pre-
cluded our ability to show significant differences by
genotype though hsCRP was significantly correlated with
both sCD14 and sCD163 levels.Only increasing age and Framingham risk score were
significantly associated with cIMT in univariable analysis
while log current CD4 T-cell counts and log sCD163
levels were candidate predictors. In the multivariable
model however only increased Framingham risk score
was significantly associated with increased cIMT while
log sCD163 and log current CD4 T-cell count were not
significantly associated with cIMT levels. Framingham
risk score is a composite index of multiple established
risk factors which are individually associated with CVD
risks and therefore its association with cIMT in HIV-
infected individuals is expected as previously found [54].
Prior studies in HIV-infected individuals have found
sCD163 levels to be associated with non-calcified plaques
[45,47], increased progression of cIMT [10] and coronary
artery calcification [35], though not all studies have re-
ported an association with CVD as we have found [55].
The exact role of sCD163 as a driver of atherosclerosis
progression is unclear. Though sCD163 is a marker of
increased monocyte activation, it has also been de-
scribed to have an anti-inflammatory role by increas-
ing the production of IL10 and inhibiting T-cell
activation [56,57].
The CD14 C-260T SNP was not significantly associated
with cIMT in this cohort. Prior studies have reported both
significant [17-19,22] and non-significant associations
[29,38,58] between the C-206T SNP and cIMT. Our
failure to demonstrate a significant association if one
truly existed could have been affected by the small sam-
ple size (power = 33%) and the low CVD risks in this
cohort. Indeed, all prior studies in East Asians that have
reported a significant association between the CD14 C-
260T SNP and CVD were in populations of high CVD
risks [33].
There were a number of important limitations in our
study. First, we only genotyped the CD14 C260T SNP in
this study while numerous other SNPs have recently
been described to additionally modulate sCD14 levels
[13]. In contrast to other SNPs associated with CVD, the
CD14 C-260T SNP has been associated with multiple
other inflammatory diseases [59-62] consistent with in-
volvement in important non-redundant biological pathways.
Second, many of our findings were probably confounded by
the small sample numbers in our cohort. The recruitment
in our study was dependent on patients re-consenting for
genetic testing from an established clinic-based cohort of
patients reporting no clinical history of CVD risk factors.
We only had 33% power to show a significant association of
cIMT with this SNP if one existed (at the 5% significance
level, presuming a ratio of 1:1) taking into account the aver-
age increased attributable risk to the T-allele in non-HIV in-
fected East Asians [33] and the baseline rate of events
(defined as increased cIMT >0.7 mm) in C-allele carriers in
our cohort.
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This is the first study to assess the relationship between
the CD14 C-260T SNP and monocyte activation, inflam-
mation and cIMT in HIV-infected individuals. We found
that the CD14 C-260T SNP was associated with increased
monocyte activation but not systemic inflammation or
cIMT in this HIV-infected cohort with low CVD risk pro-
file. Given that drivers of chronic immune activation per-
sist despite cART and that increased monocyte activation
has been associated with morbidity and mortality in
HIV-infected patients on cART, the potential influence
of this SNP in chronic HIV disease warrants further
investigation.
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